Cerebral, a startup hoping to close a healthcare gap by providing online consultations and prescriptions for mental health issues, is betting users are open to ordering medicine for anxiety, depression and insomnia through the mail.
Co-Founder and CEO Kyle Robertson told Cheddar the company connects users with a doctor via web video who is authorized to write a prescription. Later, the patient will be matched with a care manager for ongoing consultations. Cerebral, which launched last week, sends medicine to users in “discreet,” branded packaging, he said.
The company hopes to make treatments more widely available to individuals for $92 per month, which pays for a video consultation with a physician, medication via mail, and monthly check-ins with a care manager.
Those care managers act as facilitators for medication management, Robertson said. “They help flag if medication or dosage adjustments are needed and work very closely with that prescribing provider.”
Care managers provide “psycho-social support,” he said. They call users monthly and help provide services outside of medication to supplement treatment, such as meditation, mindfulness and exercise, he said. “It’s comprehensive treatment.”
Robertson co-founded the company with Ho Anh, who used to be a doctor for Hims, the startup creating products for men’s sexual health, hair loss and skin care.
The company takes liability seriously, says Robertson, as “we are treating clients’ mental health and that’s an incredibly important thing,” but “in terms of liability there is a prescriber-client relationship, so, ultimately, that is what it comes down to.”
He said the company does not provide medications like Benzodiazepines or stimulants that may be addictive and instead focuses on “non addictive” medications like beta-blockers, SSRIs and SNRIs.
“The model we built is really catered toward making sure we are being really responsible for the clients we are taking on,” he said.
YouTube will offer creators a way to rejoin the streaming platform if they were banned for violating COVID-19 and election misinformation policies that are no longer in effect.
Lukas Alpert of MarketWatch explores how networks, brands, and ad buyers absorb the shockwaves when late‑night show hosts are suddenly cut — and brought back.
A new poll finds U.S. adults are more likely than they were a year ago to think immigrants in the country legally benefit the economy. That comes as President Donald Trump's administration imposes new restrictions targeting legal pathways into the country. The Associated Press-NORC Center for Public Affairs Research survey finds Americans are more likely than they were in March 2024 to say it’s a “major benefit” that people who come to the U.S. legally contribute to the economy and help American companies get the expertise of skilled workers. At the same time, perceptions of illegal immigration haven’t shifted meaningfully. Americans still see fewer benefits from people who come to the U.S. illegally.
Shares of Tylenol maker Kenvue are bouncing back sharply before the opening bell a day after President Donald Trump promoted unproven and in some cases discredited ties between Tylenol, vaccines and autism. Trump told pregnant women not to use the painkiller around a dozen times during the White House news conference Monday. The drugmaker tumbled 7.5%. Shares have regained most of those losses early Tuesday in premarket trading.
Scott Trench, host of the BiggerPockets Money Podcast, explores how recent rate cuts, high borrowing costs, and mortgage rates are reshaping U.S. real estate.
A look into how disruption, AI, and global economic trends are transforming the modern supply chain with Jeremy Jansen, Head of Supply Chain at Wells Fargo.
